Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports Reuters 11:06AM ET, 10/26/2025 Oct 26 (Reuters) - Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter. Reuters could not immediately confirm the report. (Reporting by Dheeraj Kumar in Bengaluru; Editing by Aidan Lewis)